Oral Non-Incretin Small Molecule
Obesity / Metabolic Disorders
PreclinicalActive - Lead Optimization
Key Facts
Indication
Obesity / Metabolic Disorders
Phase
Preclinical
Status
Active - Lead Optimization
Company
About Alaunos Therapeutics
Alaunos Therapeutics is executing a dual-platform strategy to develop novel therapies for obesity and cancer. Its lead program is an oral, small molecule for obesity that deliberately avoids the incretin hormone pathway, aiming for improved tolerability and a differentiated metabolic profile, with proof-of-concept established in preclinical models. Concurrently, the company's hunTR® platform enables rapid discovery and validation of T-cell receptors for engineered cell therapies. As a micro-cap, pre-revenue public company, Alaunos represents a high-risk, high-potential investment focused on advancing these platforms toward clinical validation.
View full company profileTherapeutic Areas
Other Obesity / Metabolic Disorders Drugs
| Drug | Company | Phase |
|---|---|---|
| Mitochondrial Thermogenesis Activator | Equator Therapeutics | Pre-clinical |